Study summary
An engineered donor-cell product made stem-cell transplants safer
3.4%deaths not caused by relapse, vs 13.2% with standard transplant
What was tested
Orca-T, a donor stem-cell product enriched with regulatory T cells that calm graft-versus-host disease, against a standard transplant with tacrolimus and methotrexate, for adults with MDS or acute leukemia.
What they found
- Survival free of chronic graft-versus-host disease was much higher (hazard ratio 0.26).
- Deaths not caused by relapse were 3.4% vs 13.2%.
- Overall survival was 93.9% vs 83.1% (not statistically significant).
What it means
Transplant is the only cure for MDS; making it safer could open it to more people.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.